Furthermore, transgenic expression of the nominal T-cell receptor (TCR) targeting the KRAS mutant in recipient immune effector cells resulted in observable tumor regression: anti-KRASG12D T-cell responses cleared all mutation-positive metastatic lesions expect for one which lost the HLA-C*08:02 gene. The gene discussed is HLA-C; the disease is neoplasm.